NTHI Stock — NeOnc Technologies Holdings Inc.: Cash, EV, Pipeline

Share price

$3.26

Market cap

$97.0M

Cash

$2.0M

Enterprise value

$95.0M

Balance sheet

Cash	$2.0M
Debt	$0.0M
Net cash	$2.0M
Enterprise value	$95.0M
Basic shares	28.5M shares
Fully diluted shares	34.5M shares
Fully diluted market cap	$112.4M
Cash per share	$0.07

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading NTHI daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 10 - Mar 24	NEO100	Phase 2	Residual, Progressive or Recurrent Grade II or III Meningioma	—
Apr 11 - May 23	NEO212 Oral Capsule	Phase 1/2	Diffuse Astrocytoma, IDH-Mutant; Glioblastoma, IDH-wildtype; Brain Metastases, Adult	—
Jul 13 - Aug 24	NEO100	Phase 1	Pediatric Tumor of CNS; Pediatric Tumor of Brain; Diffuse Midline Glioma, H3 K27M-Mutant	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

NEO100

Phase 2 · Active Modality: intranasal delivery

Aliases perillyl alcohol (POH)

Indications

Recurrent malignant glioma (Grade IV IDH1-mutant GBM; Grade III IDH1-mutant astrocytoma) (Phase 2)

Status note Lead candidate. Naturally occurring monoterpenoid (POH). Phase 1 safety testing completed; Phase 2a enrollment completed and clinical data collected. Company intends to meet with FDA to discuss design of a potential Phase 3 trial.

NEO212

Phase 1 · Active Modality: oral bioconjugate (temozolomide + perillyl alcohol)

Indications

Primary and secondary malignant brain cancer (recurrent IDH1 wildtype GBM) (Phase 1)

Status note Designed to enhance CNS penetration and address MGMT-mediated temozolomide resistance. NEO212-01 Phase 1/2 dose escalation completed (MTD reached at 810 mg; RP2D 610 mg). FDA provided CMC clearance to advance to Phase 2 and indicated the program may proceed under the accelerated approval pathway. Planned Phase 2 redesigned to focus on recurrent IDH1 wildtype GBM; Type B end-of-Phase 1 meeting planned.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	NEO100
Lead indication	Residual, Progressive or Recurrent Grade II or III Meningioma
Lead phase	Phase 2
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05023018	Phase 2	Recruiting	Sponsor	Neonc Technologies, Inc.	—	Residual, Progressive or Recurrent Grade II or III Meningioma	—
NCT02704858	Phase 1/2	Active, not recruiting	Sponsor	Neonc Technologies, Inc.	—	Glioblastoma Multiforme	—
NCT06047379	Phase 1/2	Recruiting	Sponsor	Neonc Technologies, Inc.	—	Diffuse Astrocytoma, IDH-Mutant; Glioblastoma, IDH-wildtype; Brain Metastases, Adult	—
NCT06357377	Phase 1	Recruiting	Sponsor	Neonc Technologies, Inc.	—	Pediatric Tumor of CNS; Pediatric Tumor of Brain; Diffuse Midline Glioma, H3 K27M-Mutant	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Neonc Technologies, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

NTHI — NeOnc Technologies Holdings Inc.